Novagali Pharma - Board of Directors

Board members are:

Dr Alain Munoz

President of the Supervisory Board

MD, he has more than thirty years of experience in the pharmaceutical industry with R&D, Business development and corporate activities. He has held key positions at Sanofi (Vice President R&D, Vice President International Development) and Fournier (Senior Vice President of the pharmaceutical division ). Since 2000, he has developed a number of independent activities related to biopharmaceutical investment and consultancy in the healthcare sector. He also currently serves as Board member for various biopharmaceutical companies.

George Lasezkay

Vice President of the Supervisory Board

He earned BS Pharmacy, Doctor of Pharmacy and JD degrees. He has more than fifteen years of experience in the US pharmaceutical industry. Former Corporate Vice President of Corporate Development at Allergan, his unique track record counts over 60 acquisition, alliance and licensing operations mainly in ophthalmology. Since 2002, he has been active as a consultant in the pharmaceutical industry. He currently serves as director of various biopharmaceutical companies including Valentis, Collagenex Pharmaceuticals and Acuity Pharmaceuticals.

Dr Bernard Chauvin

Siparex Ventures

Ophthalmologist, he headed Laboratoires Chauvin for 18 years prior to joining Neurotech as CEO (a biotech company specialized in diseases of back of the eye). Dr. Bernard Chauvin has significant expertise in pharmaceutical development and marketing of ophthalmic products.

Philippe Peltier

Auriga Partners

Philippe Peltier joined Auriga Partners in January 1999. He specializes in investments in the life sciences, and currently serves on several boards including Nautilus Biotech (France), Mutabilis (France) and SpinX Technologies (USA). Prior to joining Auriga Partners, Philippe was an equity analyst with HSBC-CCF Securities, covering biotech and biopharma public stocks. Before, he was a business analyst at Finovelec and at Banexi specialized in venture capital investment in early stage companies. He holds a MS in Molecular Biology from the University of Paris VII and a MS in finance from ESSEC (Paris).

Remi Droller

AGF Private Equity

He holds a postgraduate degree in Molecular Biology from Paris VI University and a Masters degree in Management and Science from INA-PG/ESC Reims. Mr. Droller is investment director of AGF Private Equity, Paris, which he joined in 2003. Before that Mr. Droller spent three years working for CDC Ixis Innovation (renamed CDC Entreprises Innovation). Mr. Droller is a member of the boards of Integragen SA, France and Zealand Pharma A/S, Danemark.

Dr Jean Christophe Renondin

CDC Entreprises Innovation

Prior to joining CDC Entreprises Innovation, Jean-Christophe was Managing Director at MDS Capital, a North American Venture Capitalist Group with $1.3b under management dedicated to private investment in Biotech and Life Science areas. His responsibilities ranged from investing, building value in portfolio companies primarily located on the canadian and US East Coast, to fund raising activities.

Nava Swersky Sofer

YISSUM

Chief Executive Officer of Yissum, the technology transfer company of the Hebrew University of Jerusalem. She is a seasoned venture capitalist who has managed funds in both Israel and the United States. She joined the venture industry over ten years ago from pharmaceutical giant Ciba-Geigy (now Novartis), where she was a member of senior management at the company’s headquarters in Switzerland and in the US. She serves on the boards of many companies, primarily in the biomedical field, and has actively led the successful development of start-up companies in this field.

Raphael Wisniewski

Edmond de Rothschild Investment Partners

Mr Wisniewski is an investment director at Edmond de Rothschild Investment Partners (EDRIP) in the life sciences venture group. He sits on the board of several European life sciences companies on behalf of EDRIP. Prior to joining EDRIP in 2001, Mr. Wisniewski spent several years in London working for the hospital group General Healthcare Group and in the healthcare practices of Salomon Smith Barney and Goldman Sachs.